Taysha Gene Therapies CMO Suyash Prasad departs effective immediately

Taysha Gene Therapies, Inc.

Chief Medical Officer Suyash Prasad separated from Taysha on Jan 12, 2023 by mutual agreement.
Separation agreement terms not yet finalized; company to file further details later.
No replacement named; CFO signed the 8-K filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Suyash Prasad

Chief Medical Officer

TSHA · Taysha Gene Therapies, Inc.

Effective: 2023-01-12
Filed: January 19, 2023, 6:59 PM ET

On January 12, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) and Suyash Prasad, the Company’s Chief Medical Officer, mutually agreed to Dr. Prasad’s separation from the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Suyash Prasad departed as Chief Medical Officer at Taysha Gene Therapies, Inc..

Action: separated
Role: Chief Medical Officer

Exact text from the filing

On January 12, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) and Suyash Prasad, the Company’s Chief Medical Officer, mutually agreed to Dr. Prasad’s separation from the Company, effective immediately.

View on SEC.gov

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-010947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.